No profile data available.
Cue Biopharma, Inc. (CUE) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Boston, United States, with about 29 full-time employees.
It reported revenue of $27.47 million for fiscal year 2025, up 195.7% from fiscal year 2024, and net income of -$26.60 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $7.88 million, up 166.7% from a year before. Its market capitalization was $200.93 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Cue Biopharma reported $27.47 million in revenue for fiscal year 2025, up 195.7% from $9.29 million in fiscal year 2024. In Q2 2026 revenue was $7.88 million.
$200.93 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Zura Bio Limited (ZURA), Cabaletta Bio, Inc. (CABA), Century Therapeutics, Inc. (IPSC), Nkarta, Inc. (NKTX).